N-甲基-L-丙氨酸甲酯盐酸盐 | 35023-55-3

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 丙氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-甲基-L-丙氨酸甲酯盐酸盐
• 英文名称: N-methyl-L-alanine methyl ester
• 英文别名: methyl (2S)-2-(methylamino)propanoate；methyl N-methyl-L-alaninate；N-Me-L-Ala-OMe；(s)-Methyl 2-(methylamino)propanoate
• CAS: 35023-55-3
• 化学式: C₅H₁₁NO₂
• mdl: MFCD08458659
• 分子量: 117.148
• InChiKey: PQIUHUKRJAOTLS-BYPYZUCNSA-N

物化性质

• 沸点：
  131.3±23.0 °C(Predicted)
• 密度：
  0.946±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26
• 危险类别码：
  R22,R36
• 海关编码：
  2922499990
• 储存条件：
  存储于0°C低温环境中

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-Me-Ala-OMe
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H319: Causes serious eye irritation
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: N-Me-Ala-OMe
CAS number: 35023-55-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C5H11NO2
Molecular weight: 117.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-甲基-L-丙氨酸甲酯盐酸盐 在 Nishimura catalyst <(45.9% Rh/19.9% Pt) oxide> 氢气 作用下， 以 甲醇 为溶剂， 25.0 ℃ 、10.0 MPa 条件下， 以75%的产率得到(S)-2-(甲基氨基)丙-1-醇
  参考文献：
  名称：

  Catalytic Hydrogenation of Chiral α-Amino and α-Hydroxy Esters at Room Temperature with Nishimura Catalyst without Racemization

  摘要：

  The hydrogenation or carboxylic acid derivatives at room temperature was investigated. With a mixed Rh/Pt oxide (Nishimura catalyst), low to medium activity was observed for various alpha-amino and alpha-hydroxy esters. At 100 bar hydrogen pressure and 10% catalysts loading, high yields or tire desired amino alcohols and diols were obtained without racemization. The most suitable alpha-substituents were NH2, NHR, and 011, whereas beta-NH2 were less effective. Usually, aromatic rings were also hydrogenated, but with the free bases of amino acids as substrates, some selectivity was observed. No reaction was round for alpha-NR2, alpha-OR, and unfunctionalized esters; acids and amides, were also not reduced under these conditions. A working hypothesis for the mode or action of the catalyst is presented.

  DOI：

  10.1002/1615-4169(20011231)343:8<802::aid-adsc802>3.0.co;2-t
• 作为产物：
  描述：

  Z-L-MeAlaOMe 在 氢溴酸 作用下， 生成 N-甲基-L-丙氨酸甲酯盐酸盐
  参考文献：
  名称：

  使用氢化钠/甲基碘从氨基酸衍生物合成N-甲基氨基酸衍生物

  摘要：

  脂肪族氨基酸的 N-乙酰基-、N-苯甲酰基-和 N-羧基苯甲氧基衍生物与氢化钠/碘甲烷在含有二甲基甲酰胺的四氢呋喃中于 80°反应，以高产率得到相应的 N-甲基氨基酸甲酯，为油状。这些的皂化得到N-保护的-N-甲基氨基酸，脱羧基化得到N-甲基氨基酸甲酯氢硼化物。产品基本上是光学纯的，不含未甲基化的氨基酸衍生物。

  DOI：

  10.1139/v71-317

文献信息

• [EN] CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO<br/>[FR] CONJUGUÉS COMPRENANT DES GROUPES PEPTIDIQUES ET PROCÉDÉS ASSOCIÉS À CEUX-CI
  申请人：LEGOCHEM BIOSCIENCES INC

  公开号：WO2017089894A1

  公开（公告）日：2017-06-01

  In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

  在某些方面，本发明涉及一种抗体药物偶联物，包括：抗体；连接体；以及至少两个活性剂。在优选的实施例中，连接体包括由多个氨基酸组成的肽序列，其中至少两个活性剂通过共价键与氨基酸的侧链连接。抗体药物偶联物可以包括自焚基团，优选地是两个自焚基团。连接体可以包括O-取代的肟，例如，其中肟的氧原子被取代以与活性剂形成共价键连接；肟的碳原子被取代以与抗体形成共价键连接。
• Absolute Configurational Assignments of Secondary Amines by CD-Sensitive Dimeric Zinc Porphyrin Host
  作者：Xuefei Huang、Naoko Fujioka、Gennaro Pescitelli、Frank E. Koehn、R. Thomas Williamson、Koji Nakanishi、Nina Berova

  DOI：10.1021/ja020520p

  日期：2002.9.1

  determination of absolute configuration of secondary amines including acyclic and cyclic aliphatic amines, aromatic amines, amino acids, and amino alcohols is described. The chiral substrate is linked to the achiral carrier moiety (3-N-Boc-amino-propyl-N-Boc-amino)acetic acid 1 (BocHNCH(2)CH(2)CH(2)BocNCH(2)COOH), which after deprotection, yields a bidentate conjugate, capable of forming a 1:1 host/guest complex

  描述了用于确定仲胺绝对构型的一般手性实验方案，包括无环和环状脂肪胺、芳香胺、氨基酸和氨基醇。手性底物连接到非手性载体部分（3-N-Boc-氨基-丙基-N-Boc-氨基）乙酸1（BocHNCH（2）CH（2）CH（2）BocNCH（2）COOH），脱保护后，产生双齿缀合物，能够与二聚锌卟啉宿主 2 形成 1:1 的宿主/客体复合物。与早先报道的伯胺和仲醇的情况一样，仲胺缀合物与卟啉镊子宿主的络合图2表示立体分化过程，其中立体中心的大(L)基团(基于构象能A值指定)从卟啉结合口袋突出。这导致形成具有优选的卟啉螺旋的宿主/客体复合物，表现出强烈的激子分裂 CD 光谱。尽管仲胺偶联物的叔酰胺键周围的 Z/E 构象复杂性极大地阻碍了先前的构型分配，但发现卟啉扭曲的手性意义明显受立体中心控制。因此，在取代基的相对空间大小没有歧义的情况下，观察到的 CD 对可以用于直接分配绝对构型。此外，为了将应用扩展
• PTERIDINONE COMPOUNDS AND USES THEREOF
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20190322673A1

  公开（公告）日：2019-10-24

  The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

  本发明提供了式I的化合物或其药学上可接受的盐，以及用于治疗细胞增殖性疾病（例如癌症）的药物组合物和使用方法。
• Studies toward the Total Synthesis of Itralamide B and Biological Evaluation of Its Structural Analogs
  作者：Xiaoji Wang、Chanshan Lv、Junmin Feng、Linjun Tang、Zhuo Wang、Yuqing Liu、Yi Meng、Tao Ye、Zhengshuang Xu

  DOI：10.3390/md13042085

  日期：——

  A and B were isolated from the lipophilic extract of Lyngbya majuscula collected from the eastern Caribbean. Itralamide B (1) showed cytotoxic activity towards human embryonic kidney cells (HEK293, IC50 = 6 μM). Preliminary studies disapproved the proposed stereochemistry of itralamide. In this paper, we will provide a full account of the total synthesis of four stereoisomers of itralamide B and the

  从从东加勒比海收集的山茱Lyn的亲脂性提取物中分离出Itralamides A和B。Itralamide B（1）对人胚胎肾细胞显示出细胞毒活性（HEK293，IC50 = 6μM）。初步研究不赞成拟议的Itralamide立体化学。在本文中，我们将全面介绍Itralamide B的四种立体异构体的总合成以及从这些结构同源物的生物学测试得出的结果。
• MTKI QUINAZOLINE DERIVATIVES
  申请人：Papanikos Alexandra

  公开号：US20100029627A1

  公开（公告）日：2010-02-04

  The present invention concerns the compounds of formula the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Y represents —C 3-9 alkyl-, —C 1-5 alkyl-NR 6 —C 1-5 alkyl- or —C 1-5 alkyl-NR 7 —CO—C 1-5 alkyl-; X 1 represents —O—; X 2 represents NR 5 —C 1-2 alkyl-; R 1 represents hydrogen, halo or Het 3 -O—; R 2 represents hydrogen; R 3 represents hydroxy, C 1-4 alkyloxy- or C 1-4 alkyloxy substituted with one or two substituents each independently selected from Het 4 , hydroxy, C 1-4 alkyloxy-, C 1-4 alkyloxy-C 1-4 alkyloxy and NR 9 R 10 ; R 5 represents hydrogen or C 1-4 alkyl; R 6 represents hydrogen or C 1-4 alkyl; R 7 represents hydrogen; R 9 and R 10 each independently represent hydrogen; C 1-4 alkyl-S(═O) 2 —C 1-4 alkyl-C(═O)—; C 1-4 alkyl or C 1-4 alkyl substituted with hydroxy; Het 3 represents pyridinyl optionally substituted with C 1-4 alkyl; Het 4 represents morpholinyl, piperidinyl or piperazinyl wherein said Het 4 is optionally substituted with hydroxy-C 1-4 alkyl or C 1-4 alkyl-S(═O) 2 —C 1-4 alkyl-.

  本发明涉及具有以下结构的化合物：N-氧化物形式，药学上可接受的加成盐及其立体化异构体形式，其中Y代表-C3-9烷基-，-C1-5烷基-NR6-C1-5烷基-或-C1-5烷基-NR7-CO-C1-5烷基-；X1代表-O-；X2代表NR5-C1-2烷基-；R1代表氢，卤素或Het3-O-；R2代表氢；R3代表羟基，C1-4烷氧基或C1-4烷氧基，其中每个独立地从Het4，羟基，C1-4烷氧基，C1-4烷氧基-C1-4烷氧基和NR9R10中选择的一个或两个取代基取代；R5代表氢或C1-4烷基；R6代表氢或C1-4烷基；R7代表氢；R9和R10各自独立地代表氢；C1-4烷基-S(═O)2-C1-4烷基-C(═O)-；C1-4烷基或C1-4烷基取代羟基；Het3表示可选地取代为C1-4烷基的吡啶基；Het4表示吗啡啶基，哌啶基或吡哌啉基，其中所述的Het4可选地取代为羟基-C1-4烷基或C1-4烷基-S(═O)2-C1-4烷基-。